文献速递消化、代谢与肾脏急症

利伐沙班用于高危门诊癌症患者的血栓预防

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
PubMed 文献 · N Engl J Med · 2019-01-01
一句话结论高危门诊癌症患者每日利伐沙班10 mg在180天试验期内未显著降低静脉血栓栓塞或相关死亡,干预期内事件显著减少且大出血发生率低。

这项双盲随机试验纳入Khorana评分≥2的高危门诊癌症患者,筛查无深静脉血栓者随机接受利伐沙班10 mg每日一次或安慰剂,最长180天,每8周筛查。至第180天,主要疗效终点在利伐沙班组420例中发生25例(6.0%),安慰剂组421例中发生37例(8.8%),HR 0.66(95%CI 0.40-1.09),P=0.10,未达统计学显著。预设干预期分析中,利伐沙班组11例(2.6%)vs 安慰剂组27例(6.4%),HR 0.40(95%CI 0.20-0.80)。大出血利伐沙班组405例中8例(2.0%)vs 安慰剂组404例中4例(1.0%),HR 1.96(95%CI 0.59-6.49)。

要点

  • 至第180天,利伐沙班10 mg每日一次组主要疗效终点6.0%(25/420)vs 安慰剂组8.8%(37/421),HR 0.66(95%CI 0.40-1.09),P=0.10,未达统计学显著。
  • 预设干预期分析中,利伐沙班组主要终点2.6%(11例)vs 安慰剂组6.4%(27例),HR 0.40(95%CI 0.20-0.80)。
  • 大出血发生率利伐沙班组2.0%(8/405)vs 安慰剂组1.0%(4/404),HR 1.96(95%CI 0.59-6.49)。
  • 1080例入组患者中49例(4.5%)筛查时发现血栓未随机化;841例随机化。
  • 研究针对Khorana评分≥2(0-6分,评分越高静脉血栓栓塞风险越高)的门诊癌症患者,利伐沙班10 mg每日一次最长180天,每8周筛查。

适用人群与场景

  • 接受全身抗癌治疗的高危门诊癌症患者,Khorana评分≥2(0-6分,评分越高静脉血栓栓塞风险越高),筛查时无深静脉血栓。

诊断标准与关键阈值

  • 采用Khorana评分≥2(0-6分)界定高危门诊癌症患者。
  • 筛查时无深静脉血栓者方可随机化;1080例入组患者中49例(4.5%)筛查时发现血栓未随机化。

处置流程与药物剂量

  • 利伐沙班10 mg每日一次口服,最长180天,每8周筛查一次,对照为安慰剂。
  • 主要疗效终点为客观确认的下肢近端深静脉血栓、肺栓塞、有症状的上肢深静脉血栓或下肢远端深静脉血栓、静脉血栓栓塞所致死亡的复合终点,评估至第180天。
  • 预设支持性分析在干预期(首次接受试验药物至末次给药加2天)评估同一终点。

研究设计与关键结果

  • 双盲随机试验,1080例入组,841例随机化(利伐沙班组420例,安慰剂组421例)。
  • 至第180天主要疗效终点:利伐沙班组25/420(6.0%)vs 安慰剂组37/421(8.8%),HR 0.66(95%CI 0.40-1.09),P=0.10。
  • 预设干预期分析主要疗效终点:利伐沙班组11例(2.6%)vs 安慰剂组27例(6.4%),HR 0.40(95%CI 0.20-0.80)。
  • 大出血:利伐沙班组8/405(2.0%)vs 安慰剂组4/404(1.0%),HR 1.96(95%CI 0.59-6.49)。

证据类型、等级与局限

  • 研究类型:双盲随机对照试验(CASSINI,ClinicalTrials.gov NCT02555878),由Janssen等资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在高危门诊癌症患者中,利伐沙班治疗在180天试验期内未显著降低静脉血栓栓塞或静脉血栓栓塞所致死亡的发生率;干预期内利伐沙班使此类事件发生率大幅降低,且大出血发生率低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain.

METHODS: In this double-blind, randomized trial involving high-risk ambulatory patients with cancer (Khorana score of ≥2, on a scale from 0 to 6, with higher scores indicating a higher risk of venous thromboembolism), we randomly assigned patients without deep-vein thrombosis at screening to receive rivaroxaban (at a dose of 10 mg) or placebo daily for up to 180 days, with screening every 8 weeks. The primary efficacy end point was a composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism and was assessed up to day 180. In a prespecified supportive analysis involving the same population, the same end point was assessed during the intervention period (first receipt of trial agent to last dose plus 2 days). The primary safety end point was major bleeding.

RESULTS: Of 1080 enrolled patients, 49 (4.5%) had thrombosis at screening and did not undergo randomization. Of the 841 patients who underwent randomization, the primary end point occurred in 25 of 420 patients (6.0%) in the rivaroxaban group and in 37 of 421 (8.8%) in the placebo group (hazard ratio, 0.66; 95% confidence interval [CI], 0.40 to 1.09; P = 0.10) in the period up to day 180. In the prespecified intervention-period analysis, the primary end point occurred in 11 patients (2.6%) in the rivaroxaban group and in 27 (6.4%) in the placebo group (hazard ratio, 0.40; 95% CI, 0.20 to 0.80). Major bleeding occurred in 8 of 405 patients (2.0%) in the rivaroxaban group and in 4 of 404 (1.0%) in the placebo group (hazard ratio, 1.96; 95% CI, 0.59 to 6.49).

CONCLUSIONS: In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period. During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding. (Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019. PMID: 30786186. doi:10.1056/NEJMoa1814630

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。